Agilis Biotherapeutics
Lynnfield
About Agilis Biotherapeutics
Agilis Biotherapeutics develops DNA therapeutics for patients with rare diseases of the central nervous system (CNS) that single-gene defects cause. Its technology enables precise targeting and restoration of lost gene function while avoiding unintended off-target effects. Agilis Biotherapeutics also provides DNA therapeutics for patients with AADC Deficiency, a rare CNS disorder arising from reductions in the enzyme aromatic L-amino acid decarboxylase (AADC) that causes the inability to develop any motor strength and control resulting in breathing, feeding, and swallowing problems. Moreover, it offers DNA therapeutics for Friedreich’s Ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene, which causes reduced production of the frataxin protein, and DNA therapeutics for Angelman Syndrome (AS), a rare genetic, neurological disorder characterized by severe developmental delays. Agilis Biotherapeutics has a strategic partnership with Intrexon Corporation. It began its operation in 2013, with its headquarters in Lynnfield, Massachusetts.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $20.7M
- Funding stage: M&A
- Last round: Series Unknown (Feb 2017)
- Website: agilisbio.com
- Phone: 214-706-4340
Industries & Categories
Biotechnology, Health Care, Personal Health, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/agilis-biotherapeutics-149999 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.